Updated Jul 16, 2026
Cline Christopher R. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $772K.
Christopher R. Cline is the Chief Financial Officer of Travere Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for rare kidney, liver, and metabolic diseases. He has been involved in the financial operations of the company, contributing to its strategic initiatives.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 310 | $43.95 | $14K |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 2.2K | $46.65 | $102K |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | M — Option exercise | 4.2K | $0.00 | |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 1.0K | $42.61 | $43K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 7.2K | $41.93 | $304K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 9 | $41.07 | $370 |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 65 | $28.85 | $2K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | A — Grant or award | 14.0K | $0.00 | |
| 2026-02-05 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale [10b5-1] | 110 | $32.90 | $4K |
| 2026-02-05 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.6K | $32.14 | $53K |
| 2026-02-04 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 7.2K | $32.12 | $233K |
| 2026-02-04 | TVTX | Travere Therapeutics, Inc. | A — Grant or award | 28.1K | $0.00 | |
| 2025-09-03 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 119 | $19.71 | $2K |
| 2025-09-03 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 454 | $18.20 | $8K |
| 2025-08-27 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 470 | $17.31 | $8K |
Christopher R. Cline is the Chief Financial Officer of Travere Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for rare kidney, liver, and metabolic diseases. He has been involved in the financial operations of the company, contributing to its strategic initiatives.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 12 open-market sales ($772K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Cline Christopher R. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.